Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI